 | | Vol. 12.41 – 4 November, 2021 |
| |
|
|
| Researchers showed that discoidin domain receptor 1 (DDR1), a collagen receptor with tyrosine kinase activity, instigated immune exclusion by promoting collagen fiber alignment.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists present evidence that the extracellular DNA (eDNA)-based architecture of biofilm development relied on the rare Z-form, and demonstrated that the universal bacterial DNABII family of proteins stabilized both bacterial- and host-eDNA in the Z-form in situ.
[Cell] |
|
|
|
| Investigators proposed an elegant and gentle solvent consumption strategy to slowly disrupt the thermodynamic stability of a biopolymer solution to slightly induce the molecule chains to in situ self-assemble into nanostructures for regulating the rheological properties.
[ACS Nano] |
|
|
|
| Researchers defined functions for numerous extracellular vesicle cargo proteins in biofilm matrix assembly and drug resistance, as well as in fungal cell adhesion and dissemination.
[Nature Communications] |
|
|
|
| The authors investigated mature human hypertrophic scars and developing scars in mice at single cell resolution. They delineated the genetic landscape of hypertrophic scars and presented insights into mechanisms involved in hypertrophic scar formation.
[Nature Communications] |
|
|
|
| Investigators developed a methacrylated photocurable silk fibroin bioink for digital light processing 3D bioprinting to generate structures with high mechanical stability and biocompatibility for tissue engineering applications.
[Nature Protocols] |
|
|
|
| Scientists revealed that β2 adrenergic receptor (β2-AR) expression on myeloid-derived suppressor cells (MDSCs) increased with tumor growth and that the β2-AR stress pathway drove the immune-suppressive activity of MDSCs by altering their metabolism.
[Cell Reports] |
|
|
|
| Second harmonic generation assays with mouse xenograft models and human samples demonstrated cancer-associated fibroblasts-derived hyaluronan and proteoglycan link protein 1 (HAPLN1) increased tumor invasiveness through ECM remodeling.
[Gastric Cancer] |
|
|
|
| The authors screened the circular RNAs (circRNA) influencing matrix metalloproteinase-9 (MMP9) through the competing endogenous RNA network and evaluated the prognostic value of these circRNAs for acute ischemic stroke.
[European Journal of Neurology] |
|
|
|
| Investigators synthesized biodegradable polymeric nanoparticles loaded with darunavir and luminescent, nontoxic carbon dots, and investigated their ability to permeate through an artificial blood–brain barrier and to inhibit in vitro matrix metalloproteinase-9.
[ACS Chemical Neuroscience] |
|
|
|
| Researchers demonstrated marked and synergistic upregulation of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 by IL-1α, TNF-α, and TGF-β in osteoarthritis synovial fibroblasts.
[Laboratory Investigation] |
|
|
|
| The authors investigated the possibility that periostin secreted by fibroblasts derived from idiopathic pulmonary fibrosis lung might have affected the proliferation of non-small cell lung cancer cells.
[Scientific Reports] |
|
|
|
| Scientists developed an in vitro model of adipose tissue to study adipocyte-fibroblast crosstalk in a hypoxic environment. The model was used to investigate the effect of hypoxia on adipocyte mechanical properties via ras homolog gene family member A (RhoA)/Rho-associated coiled-coil kinases signaling pathways.
[Scientific Reports] |
|
|
|
|
| The authors summarize the two major nanomedicine strategies to circumvent intratumor ECM barriers: regulating the physiochemical properties of nanomedicines and remodeling the components and structure of the ECM.
[Advanced Healthcare Materials] |
|
|
|
|
| Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.
[Precigen, Inc.] |
|
|
|
| OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, announced the initiation of a Phase I/II study of OR2805 in patients with advanced cancer.
[OncoResponse] |
|
|
|
|
| November 23 – 26, 2021
Ibaraki, Japan & Online |
|
|
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
| | Malm̦, Sweden РLund University |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
